Vanda Pharmaceuticals: all 82 studies

Page 1 of 1. Open to participants first (17), then studies with results posted, then the rest; newest registration first within each.

• Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative ColitisRecruitingNCT07686081Phase 3
• A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist UseRecruitingNCT07446439Phase 3
• Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque PsoriasisRecruitingNCT07362017Phase 3
• An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry EyeRecruitingNCT07179055Phase 2
• Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled HypertensionRecruitingNCT07090161Phase 2
• Randomized Withdrawal Study in Patients With SchizophreniaRecruitingNCT06961968Phase 3
• Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric InsomniaRecruitingNCT06953869Phase 3
• Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive DisorderRecruitingNCT06830044Phase 3
• Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) and the CRY1Δ11 VariantRecruitingNCT06701396Phase 3
• A Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry EyeRecruitingNCT06296966Phase 2
• Safety and Tolerability of Open-Labeled Iloperidone in AdolescentsRecruitingNCT05648591Phase 4
• Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep DisturbancesRecruitingNCT05361707Phase 3
• Single-Patient Expanded Access Protocol for Tradipitant In A Single Patient With GastroparesisAvailableNCT04474990
• ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 InfectionEnrolling by invitationNCT04326426Phase 3
• Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic MalignanciesRecruitingNCT03838926Phase 1
• Development of Clinical Database of Individuals With Smith-Magenis Syndrome and Sleep DisturbancesRecruitingNCT03154697
• Patient Registry of Blind Subjects With Sleep-related ProblemsRecruitingNCT01195558
• Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion SicknessCompletedNCT05903924Phase 3Results posted
• Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPPTerminatedNCT05366855Phase 3Results posted
• Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPPCompletedNCT05352893Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Hidradenitis SuppurativaCompletedNCT04856930Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Acne VulgarisCompletedNCT04856917Phase 2Results posted
• Effects of Tradipitant on Satiation, Gastric Volume, Gastric Accommodation, and Gastric Emptying in Healthy VolunteersCompletedNCT04849559Phase 1/2Results posted
• Evaluation of Efficacy and Safety of Iloperidone in the Acute Treatment of Manic or Mixed Episodes Associated With Bipolar I DisorderCompletedNCT04819776Phase 3Results posted
• A Study to Evaluate of the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Acneiform RashTerminatedNCT04697069Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With IchthyosisTerminatedNCT04697056Phase 2Results posted
• Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History of Ocular AllergiesCompletedNCT04622345Phase 2Results posted
• Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion SicknessCompletedNCT04327661Phase 3Results posted
• Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE2)TerminatedNCT04140695Phase 3Results posted
• Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic GastroparesisCompletedNCT04028492Phase 3Results posted
• Motion Sifnos: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion SicknessCompletedNCT03772340Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar PustulosisCompletedNCT03633396Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Generalized Pustular PsoriasisCompletedNCT03619902Phase 2Results posted
• Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE)CompletedNCT03568331Phase 3Results posted
• Evaluating the Effects of Tasimelteon vs. Placebo on Jet Lag Type InsomniaCompletedNCT03373201Phase 3Results posted
• A Proof of Concept Study to Evaluate the Effects of Tasimelteon and Placebo in Travelers With Jet Lag DisorderCompletedNCT03291041Phase 2Results posted
• Study to Assess the Efficacy of VLY-686 in Relieving Symptoms of GastroparesisCompletedNCT02970968Phase 2Results posted
• Tradipitant in Treatment-resistant Pruritus Associated With Atopic DermatitisCompletedNCT02651714Phase 2Results posted
• Open Label Study to Assess the Absolute Bioavailability of Tasimelteon (HETLIOZ™)CompletedNCT02130999Phase 4Results posted
• Proof of Concept of VLY-686 in Subjects With Treatment-Resistant Pruritus Associated With Atopic DermatitisCompletedNCT02004041Phase 2Results posted
• Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake DisorderCompletedNCT01430754Phase 3Results posted
• Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive DisorderCompletedNCT01428661Phase 2/3Results posted
• Relapse Prevention Study in Patients With SchizophreniaCompletedNCT01291511Phase 3Results posted
• Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake DisorderCompletedNCT01163032Phase 3Results posted
• VEC-162 Study in Adult Patients With Primary InsomniaCompletedNCT00548340Phase 3Results posted
• Safety and Efficacy of VEC-162 on Circadian Rhythm in Healthy Adult VolunteersCompletedNCT00490945Phase 2Results posted
• VEC-162 Study in Healthy Adult Volunteers in a Model of InsomniaCompletedNCT00291187Phase 3Results posted
• Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute SchizophreniaCompletedNCT00254202Phase 3Results posted
• Treatment of Charcot-Marie-Tooth Disease, Axonal, Type 2S (CMT2S) in an Individual PatientActive, not recruitingNCT07223632Phase 1/2
• Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety DisorderActive, not recruitingNCT07221578Phase 3
• Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe OnychomycosisActive, not recruitingNCT07065773Phase 2
• Open Label Safety Study of Tradipitant in Idiopathic and Diabetic GastroparesisCompletedNCT06836557Phase 3
• A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist UseCompletedNCT06804603Phase 2
• Food Effect Study of VHX-896 in Healthy VolunteersCompletedNCT06803290Phase 1
• Pharmacokinetic Study of VHX-896 and Iloperidone Tablets Under Steady-State ConditionsCompletedNCT06494397Phase 1
• Evaluation of Next-Day Residual Effects of Tasimelteon Compared With Placebo and Active Control in Healthy SubjectsCompletedNCT06323655Phase 1
• Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion SicknessActive, not recruitingNCT06138613Phase 3
• Bioequivalence Study Between Tasimelteon Capsule Formulation and Liquid Suspension Formulation in Healthy VolunteersCompletedNCT05572281Phase 1
• A Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease PsychosisWithdrawnNCT05344365Phase 2
• Bioequivalence Study Between VHX-896 Tablets and Iloperidone Tablets in Healthy VolunteersCompletedNCT04969211Phase 1
• Evaluating the Effects of VQW-765 vs. Placebo in Performance AnxietyCompletedNCT04800237Phase 2
• A Study to Evaluate Iloperidone Long-acting Injection (LAI) for the Treatment of SchizophreniaCompletedNCT04712734Phase 1
• Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)CompletedNCT04652882Phase 3
• WGS Analysis of COVID-19 Positive PatientsCompletedNCT04353401
• Evaluating a New Iloperidone Titration Scheme in Bipolar I Disorder or SchizophreniaCompletedNCT04127058Phase 1
• Study of the Pharmacokinetics and Safety of Tasimelteon in Children and AdolescentsCompletedNCT02776215Phase 1
• Study to Assess the Effect of Multiple Doses of Tradipitant on CYP3A4 Using Midazolam as a Substrate in Healthy SubjectsCompletedNCT02621385Phase 1
• An Observational Study to Investigate the Effects of Rapid Transmeridian TravelCompletedNCT02560103
• Evaluating the Effects of Tasimelteon vs Placebo on Sleep Disturbances in SMSCompletedNCT02231008Phase 2/3
• Observational Study to Investigate the Melatonin and Cortisol Circadian Rhythms of Individuals With Smith-Magenis Syndrome (SMS)Status unknownNCT02180451
• Study of Itch Control by VLY-686 in Healthy Volunteers After Intradermal Injections of Substance PCompletedNCT01919944Phase 1
• Pharmacokinetics of Tasimelteon Alone and in Combination With a CYP3A4 Inhibitor, Ketoconazole, or a CYP3A4 Inducer, Rifampin.CompletedNCT01637636Phase 1
• Evaluation of the Pharmacodynamic and Pharmacokinetic Interactions of Tasimelteon and EthanolCompletedNCT01578057Phase 1
• Pharmacokinetics of Tasimelteon Alone and in Combination With CYP1A2 Inhibitor, FluvoxamineCompletedNCT01540500Phase 1
• Pharmacokinetics of Tasimelteon in Subjects With Renal Impairment and Matched Control Subjects With Relatively Normal Renal FunctionCompletedNCT01526746Phase 1
• Tolerability and Pharmacokinetics of Iloperidone in Adolescent PatientsCompletedNCT01495169Phase 1
• Effects of Smoking, Age and Body Size on Pharmacokinetics, Safety and Tolerability on Tasimelteon in Healthy SubjectsCompletedNCT01477619Phase 1
• Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light PerceptionCompletedNCT01429116Phase 3
• A Study to Assess the Effect Tasimelteon on the Cytochrome P450 3A4 and 2C8 Enzymes in Healthy SubjectsCompletedNCT01402076Phase 1
• Pharmacokinetics of Tasimelteon in Subjects With Mild or Moderate Hepatic ImpairmentCompletedNCT01271387Phase 1
• Safety Study of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder in Blind Individuals With No Light PerceptionActive, not recruitingNCT01218789Phase 3
• VSF-173 Study in Healthy Adult Volunteers for Treatment of Induced Excessive SleepinessCompletedNCT00467441Phase 2

← Vanda Pharmaceuticals overview and focus areas